Heart Matters

The CORALreef Lipids trial helped establish the clinical evidence supporting the FDA approval of enlicitide for LDL-C management. Join Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, for a discussion of the trial's efficacy, safety, and durability. She also explores key considerations for integrating this therapy into clinical practice.

As the drivers of cardiovascular disease have shifted over time, so have the tools used to estimate risk. Dr. Roger Blumenthal explains why the PREVENT-ASCVD equations represent an important advance over traditional models and what that means for more accurate, individualized preventive care. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.

Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a more careful evaluation for underlying causes and risk becomes important.4 That’s why Dr. Charles Turck sits down with Dr. Erin Michos to discuss what sHTG is, why it’s so important to identify, and how we can effectively manage this condition to improve patients’ overall health and reduce complication risk. Dr. Erin Michos is a Professor of Medicine, Director of Women’s Cardiovascular Health, and Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine.

References:

1. Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2025;22:100978. doi:10.1016/j.ajpc.2025.100978
2. Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. doi:10.1186/s12944-021-01488-8
3. Sikora Kessler A, Baum SJ, Kutrieb E, et al. Rates …

The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, joins us to explain how clinicians can combine PREVENT risk estimates with risk-enhancing factors, coronary artery calcium scoring, and shared decision-making to improve cardiovascular prevention strategies. Dr. Blumenthal is also the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.

What will the future of transthyretin amyloid cardiomyopathy (ATTR-CM) care look like? Dr. Frederick Ruberg joins us to share his perspective on the advances that may shape the next phase of patient care, from screening and therapeutic strategies to expanded genetic testing aimed at identifying patients earlier. He's the Chief of Cardiovascular Medicine at Boston Medical Center and Thomas J. Ryan Professor of Cardiovascular Medicine at Boston University Chobanian and Avedisian School of Medicine.

In women, hypertension follows a distinct biological and clinical course that evolves across reproductive and menopausal transitions, but its long-term implications remain underrecognized and undertreated. In this expert-led discussion, Dr. Shelina Ramnarine and Dr. Payal Kohli examine key considerations in managing hypertension in women and explore practical strategies to improve risk assessment and patient education. Dr. Kohli is an Associate Adjunct Professor at Johns Hopkins University and Duke University, as well as the Founder and Medical Director of Cherry Creek Heart in Aurora, Colorado.

This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.

With increasing recognition and more accessible diagnostic tools, ATTR-CM can no longer be overlooked in patients with atypical heart failure presentations. Dr. Valmiki Maharaj shades insights on connecting clinical clues, confirming diagnosis efficiently, and acting earlier to meaningfully impact long-term outcomes. He's the Director of the Heart Failure Clinic, the Cardiac Amyloidosis Clinic, and the Cardiovascular Disease Fellowship Program at the University of Minnesota Medical School.

Even with growing awareness of transthyretin amyloid cardiomyopathy (ATTR-CM), delays in diagnosis remain a significant challenge. That's why Dr. Ronald Witteles, Professor of Cardiovascular Medicine at Stanford Medicine and Co-Director of the Stanford Amyloid Center, joins us to share practical strategies for recognizing ATTR-CM, implementing the appropriate diagnostic pathway, and overcoming common testing pitfalls.

What clinical clues should raise suspicion for transthyretin amyloid cardiomyopathy (ATTR-CM)? Find out as Dr. Ronald Witteles examines the cardiac and extracardiac manifestations that can help us recognize this often-overlooked disease. He's a Professor of Cardiovascular Medicine at Stanford Medicine and the Co-Director of the Stanford Amyloid Center and Multidisciplinary Sarcoidosis Program.

When blood pressure remains uncontrolled despite treatment, adding more medications may not address the underlying cause. In this expert-led discussion, Drs. Jan Basile and Michael Bloch join Dr. Steve Jackson to examine often-overlooked drivers of hypertension, including aldosterone excess, volume overload, medication adherence, and blood pressure measurement challenges. Learn how a deeper understanding of these drivers can help us distinguish resistant hypertension from pseudo-resistance and individualize treatment decisions for our patients. Dr. Basile is a Professor in the Division of Cardiology at the Medical University of South Carolina in Charleston. Dr. Bloch is a Clinical Assistant Professor in the Department of Internal Medicine at the University of Nevada School of Medicine and the Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Institute for Heart and Vascular Health in Reno.

This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.